Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982587 | 0.89 | MAPK14 (0.65) | MAPK14 | |
| SCHEMBL11982555 | 0.86 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL11982577 | 0.85 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL11982650 | 0.85 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL11982576 | 0.83 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL11982590 | 0.82 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL12936169 | 0.80 | MAPK14 (0.54) | MAPK14HTT | |
| SCHEMBL1417448 | 0.80 | MAPK14 (0.54) | MAPK14HTT | |
| SCHEMBL1417056 | 0.80 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL1384294 | 0.80 | MAPK14 (0.59) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242117-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885HTT 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.